Insights
Search Results
Client Highlights
2.25.26
Wilson Sonsini Advises SambaNova on $350 Million Series E Financing
On February 24, 2026, SambaNova, a leader in next‑generation AI infrastructure, announced that it has raised more than $350 million in investment from new and existing investors. The oversubscribed Series E round was led by Vista Equity Partners and Cambium Capital, with strong participation from Intel Capital. Wilson Sonsini Goodrich & Rosati advised SambaNova on the transaction.
Client Highlights
8.07.25
Wilson Sonsini Advises Siemens Financial Services on Terra CO2’s $124.5 Million Series B
On July 2, 2025, Terra CO2 (Terra), a leading U.S.-based low-carbon building materials company, announced its Series B funding, securing $124.5 million in new equity capital. In addition to the Series B co-leads Breakthrough Energy Ventures, Eagle Materials, GenZero, and Just Climate, the round included major investment from Barclays Climate Ventures. Additional strategic investors to join the round included Prologis, Cemex, and Siemens Financial Services. In addition to the equity raise, Silicon Valley Bank, a division of First Citizens Bank, and Stifel Bank co-led the provision of a credit facility furnishing Terra additional financial flexibility. The funding will also support expanding Terra’s offices and industrial facilities. Wilson Sonsini Goodrich & Rosati advised Siemens Financial Services on the transaction.
Client Highlights
4.22.25
Wilson Sonsini Advises Altruist on $152 Million Series F Financing
On April 22, 2025, Altruist, the modern custodian for RIAs, announced $152 million in Series F funding led by GIC, a global institutional investor. Salesforce Ventures, Geodesic Capital, Baillie Gifford, Carson Family Office, ICONIQ Growth, and a select group of additional partners also participated. The round values the company at approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Altruist on the transaction.
The Series F funding follows a landmark year. In 2024, Altruist launched a suite of new products, including a high-yield cash account, automated and scalable tax management tools, and a fully digital native fixed-income trading experience. The company achieved triple-digit growth in key metrics such as revenue, brokerage accounts, and advisors served.
The Wilson Sonsini team that advised Altruist on the transaction included:
The Series F funding follows a landmark year. In 2024, Altruist launched a suite of new products, including a high-yield cash account, automated and scalable tax management tools, and a fully digital native fixed-income trading experience. The company achieved triple-digit growth in key metrics such as revenue, brokerage accounts, and advisors served.
The Wilson Sonsini team that advised Altruist on the transaction included:
Client Highlights
1.16.25
Wilson Sonsini Advises Smith Point Capital on Prophecy’s $47 Million Series B-1
On January 16, 2025, Prophecy, a leading data copilot company, announced the completion of a $47 million Series B-1 funding round. The round was led by Smith Point Capital, with HSBC joining as a new investor. Existing investors, including Berkeley SkyDeck, DallasVC, Insight Partners, JPMorgan Chase, and SignalFire, also participated. Wilson Sonsini Goodrich & Rosati advised Smith Point Capital on the transaction.
Newsletters
3.18.24
The Scramble: 2023 Gaming Legal Year in Review
Wilson Sonsini's The Scramble: 2023 Gaming Legal Year in Review provides an overview of the gaming industry and legal highlights from 2023. The report underscores the significant influence of artificial intelligence (AI) in the gaming realm in 2023 and anticipates further substantial impacts. The Scramble also features a collection of EGG’s industry-leading publications from the last year.
Client Highlights
3.06.24
Wilson Sonsini Represents SK Growth Opportunities Corporation in $7.3 Billion Business Combination with Webull Corporation
On February 28, 2024, SK Growth Opportunities Corporation (SK Growth), a publicly traded special purpose acquisition company, and Webull Corporation (Webull), a leading digital investment platform, announced a business combination through which Webull will become a publicly listed company. The transaction values the combined business at a pro forma enterprise value of approximately $7.3 billion, assuming no further redemptions by SK Growth shareholders. A wholly-owned subsidiary of SK Inc., a leading global conglomerate based in the Republic of Korea, is the anchor investor in SK Growth’s sponsor. Webull is the owner of the popular Webull platform, which provides a full suite of financial products to 20 million registered users globally.
Client Highlights
1.12.24
Firm Advises JIXING on Acquisition of BIIB131 from Biogen
On January 11, 2024, Ji Xing Pharmaceuticals (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved patients with serious and life-threatening diseases, announced the acquisition of BIIB131 from Biogen for clinical development. Wilson Sonsini Goodrich & Rosati advised JIXING on the transaction.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
BIIB131 is an investigational drug for acute ischemic stroke (AIS). Its proposed mechanism of action includes both thrombolytic and anti-inflammatory activities. By restoring critical blood flow following acute stroke, it may benefit more patients over current standard of care by extending the otherwise short treatment window.
Client Highlights
1.12.24
Wilson Sonsini Advises JIXING on Strategic Collaborations with TMS
On January 11, 2024, TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that they have entered into a strategic partnership established subsequent to the assignment of an option agreement from Biogen MA Inc. (Biogen) to JIXING, originally between TMS and Biogen, followed by an amendment immediately in effect upon the assignment. Wilson Sonsini Goodrich & Rosati advised JIXING on the transaction.
TMS and JIXING will form a collaborative partnership to globally develop TMS-007—a novel antithrombotic agent developed for the treatment of acute ischemic stroke (AIS)—with TMS regaining royalty-free Japan rights while JIXING will lead the development and commercialization of TMS-007 in the rest of the world. TMS and JIXING will join forces to expeditiously develop and launch TMS-007 globally, facilitated by the formation of a Joint Development Committee. In addition, TMS will receive an upfront payment of $5 million in the form of JIXING equity, up to $12.5 million in development milestones, up to $355 million in commercial milestones, and tiered royalties consistent with the original Option Agreement.
Concurrently, JIXING licenses to TMS exclusive Japan rights of JX09. JX09 is an oral, novel, small molecule ASI in development for the treatment of resistant and/or uncontrolled hypertension by JIXING, which is planned to enter into a first-in-human Phase 1 clinical trial in early 2024.
The Wilson Sonsini team that advised JIXING on the transactions included partners Michael Hostetler, Farah Gerdes, Mark Bellomy, Greg Broome, and Jen Fang; associates Zack Burns, TJ Tingjie Li, Ying Chen, Brandon King, Christina Fuleihan, Hee Min Noh, and Zamin Raza; and patent agent Jamie Gleason-Bremer.
For more information, please see the companies’ news release.
TMS and JIXING will form a collaborative partnership to globally develop TMS-007—a novel antithrombotic agent developed for the treatment of acute ischemic stroke (AIS)—with TMS regaining royalty-free Japan rights while JIXING will lead the development and commercialization of TMS-007 in the rest of the world. TMS and JIXING will join forces to expeditiously develop and launch TMS-007 globally, facilitated by the formation of a Joint Development Committee. In addition, TMS will receive an upfront payment of $5 million in the form of JIXING equity, up to $12.5 million in development milestones, up to $355 million in commercial milestones, and tiered royalties consistent with the original Option Agreement.
Concurrently, JIXING licenses to TMS exclusive Japan rights of JX09. JX09 is an oral, novel, small molecule ASI in development for the treatment of resistant and/or uncontrolled hypertension by JIXING, which is planned to enter into a first-in-human Phase 1 clinical trial in early 2024.
The Wilson Sonsini team that advised JIXING on the transactions included partners Michael Hostetler, Farah Gerdes, Mark Bellomy, Greg Broome, and Jen Fang; associates Zack Burns, TJ Tingjie Li, Ying Chen, Brandon King, Christina Fuleihan, Hee Min Noh, and Zamin Raza; and patent agent Jamie Gleason-Bremer.
For more information, please see the companies’ news release.
Client Highlights
5.18.23
Wilson Sonsini Advises Ambient Fuels on Investment from Generate Capital
On May 17, 2023, Generate Capital, a leading sustainable infrastructure investment and operating company, announced it made an investment in Ambient Fuels, a pioneering developer that builds green hydrogen projects to support the decarbonization of heavy industries and transportation. The company’s technology-agnostic approach works with any renewable energy source to support decarbonization at scale. With experience across both conventional and renewable energy as well as industrial and chemical processes, the Ambient Fuels team offers deep development and technical expertise. The agreement between Generate Capital and Ambient Fuels includes a commitment to fund up to $250 million of green hydrogen infrastructure.
Client Highlights
4.10.23
Wilson Sonsini Advises SOLARCYCLE on Infrastructure Financing
On March 15, 2023, SOLARCYCLE, a tech-driven recycling company focused on producing sustainable materials at scale for the solar industry, announced that it has raised $30 million in Series A funding, consisting of both company equity and infrastructure financing. This latest round brings the company’s total funding to $37 million, since its inception a year ago. Wilson Sonsini Goodrich & Rosati advised SOLARCYCLE on the infrastructure financing.
Client Highlights
2.28.23
Wilson Sonsini Advises RTW Investments on $45 Million Series B1 Financing for Oricell Therapeutics
On February 28, 2023, Oricell Therapeutics Co., Ltd, a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, announced the close of a $45 million Series B1 investment round after the completion of a $125 million Series B fundraise in July 2022. The round was led by premier global industry investors RTW Investments, LP and Qatar Investment Authority, with participation from existing investors, including Qiming Venture Partners and C&D Emerging Industry Equity Investment. The new injection of capital will be utilized primarily to support the company's core product clinical development in the U.S. With this new funding, the company is now well-positioned to expand its products to the U.S., specifically OriCAR-017, a GPRC5D CAR-T therapeutic that treats relapsed and refractory multiple myeloma, which is a product currently on the stage of IND enabling both in the U.S. and China.